On March 2, 2025, Arbutus Biopharma and Genevant Sciences agreed on patent litigation related to Moderna's vaccine, and on March 3, 2025, Arbutus terminated its license agreement with Moderna for non-payment of royalties, while also filing lawsuits against Moderna for patent enforcement.